Good for Epidiolex, but rescheduling overreaches on CBD

U.S. Dept. of Justice, DEA

A rescheduling that makes CBD-based drug Epidiolex legal has been applauded as a win for cannabinoid-based therapies, but critics say the ruling is another case of the U.S. Drug Enforcement Administration (DEA) overstepping its bounds.

You need to login to view the rest of the content. Please . Not a Member? Join Us

Subscribe to HT Newsletter

* indicates required